评估 EDIT-B® 血液检测对重度抑郁发作患者健康状况的影响。临床效用和医疗经济方面 (SEM EDIT-B)
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.
Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.
The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.
Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.
In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Benjamin Dubuc
- 邮箱:benjamin.dubuc@alcediag-alcen.com
研究联系人备份
- 姓名:Mary Menhem, PharmD, MSc
- 电话号码:+33788970700
- 邮箱:mary.menhem@alcediag-alcen.com
学习地点
-
-
-
Erstein、法国
- 尚未招聘
- CH Erstein
-
接触:
- Geraldine Pfleger, Dr
- 电话号码:+33 3 90 64 21 46
- 邮箱:geraldine.pfleger@ch-erstein.fr
-
首席研究员:
- Geraldine Pfleger, Dr
-
Issy-les-Moulineaux、法国
- 尚未招聘
- AP-HP Corentin Celton
-
接触:
- Nicolas Hoertel, Pr
- 电话号码:+33 1 58 00 44 21
- 邮箱:nicolas.hoertel@aphp.fr
-
首席研究员:
- Nicolas Hoertel, Pr
-
La Roche-sur-Foron、法国
- 尚未招聘
- Etablissement Public de Santé Mentale (EPSM) 74
-
接触:
- Rocco De Filippis, Pr
- 电话号码:+33 749121443
- 邮箱:defilippis-r@ch-epsm74.fr
-
首席研究员:
- Rocco De Filippis, Pr
-
Lyon、法国
- 招聘中
- Clinique Villa des Roses
-
接触:
- Pascal Frilloux, Dr
- 电话号码:+33 4 78 15 00 00
- 邮箱:pascal.frilloux-ext@inicea.fr
-
首席研究员:
- Pascal Frilloux, Dr
-
Montrond-les-Bains、法国
- 招聘中
- Clinique Le Clos Montaigne
-
接触:
- Christophe Aimo, Dr
- 电话号码:+33 4 77 36 01 00
- 邮箱:christophe.aimo@inicea.fr
-
首席研究员:
- Christophe Aimo, Dr
-
Paris、法国
- 招聘中
- GHU Paris Psychiatrie et Neurosciences
-
接触:
- Juan Zambrano
- 电话号码:+33145658153
- 邮箱:juan.zambrano@ghu-paris.fr
-
首席研究员:
- Chantal Henry, Pr
-
Ville-d'Avray、法国
- 尚未招聘
- Clinique Médicale de Ville d'Avray
-
接触:
- Jérôme Dischamps
- 电话号码:+33147094314
- 邮箱:jdischamps@wanadoo.fr
-
首席研究员:
- Jérôme Dischamps
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
-
Age between 18 and 65 years, gender indifferent
-
Benefitting from health insurance coverage
-
Having signed an informed consent and agreed to follow the study protocol to completion
-
Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:
- More than 3 episodes of MDE in personal medical history
- Psychotic symptoms
- Family history of bipolar disorder
- Onset of the first MDE before the age of 25
- Atypical symptoms or mixed features during depressive episodes
- Addiction
- Personal history of suicide attempts
- Resistance to antidepressants
- Postpartum depression within 6 months of birth
Exclusion Criteria:
- Depression in the context of schizophrenia or autism spectrum disorder
- Patient with a well-established diagnosis of bipolar disorder
- Patients who is already receiving a mood stabilizer
- Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
- Neurodegenerative diseases
- Pregnant women
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:With EDIT-B test result
The investigator will have the EDIT-B® test result to guide the treatment strategy. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
|
安慰剂比较:Without EDIT-B test result
The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
大体时间:4 months (from inclusion visit to 15-16 weeks visit)
|
Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint. |
4 months (from inclusion visit to 15-16 weeks visit)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.